The Food and Drug Administration has approved the Genesys HTA System of Boston Scientific Corp. for treatment of menorrhagia, or abnormally heavy and prolonged menstrual bleeding.
The system includes a hardware and software unit that controls the procedure through tubing and a sheath of heated saline solution to the endometrial (interior) lining of the uterus.
The procedure can be done in a hospital outpatient setting under general anesthesia or a physician office using a local anesthetic.
An estimated 10 million women in the United States have menorrhagia, according to the Natick, Mass.-based vendor. More information is available at bostonscientific.com.
Register or login for access to this item and much more
All Health Data Management content is archived after seven days.
Community members receive:
- All recent and archived articles
- Conference offers and updates
- A full menu of enewsletter options
- Web seminars, white papers, ebooks
Already have an account? Log In
Don't have an account? Register for Free Unlimited Access